Episode

This Fortnight in Medicine XXVII

Podcast
Sensible Medicine
Published
Jun 3, 2026
Duration seconds
1981
Processing state
not_requested
Canonical source
https://www.sensible-med.com/p/this-fortnight-in-medicine-xxvii
Audio
https://api.substack.com/feed/podcast/199498933/252ca2c3e8192dfd1501c4f69cea904d.mp3
JSON
/v1/public/podcasts/sensible-medicine-5998897/episodes/this-fortnight-in-medicine-xxvii
Markdown
/podcast/sensible-medicine-5998897/this-fortnight-in-medicine-xxvii.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/sensible-medicine-5998897/episodes/this-fortnight-in-medicine-xxvii/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/sensible-medicine-5998897/this-fortnight-in-medicine-xxvii.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy * Previously discussed on Fornight XXII: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe